- Document Number:
20210138012
- Appl. No:
17/150168
- Application Filed:
January 15, 2021
- نبذة مختصرة :
A method for or treating respiratory disease according to an embodiment includes administering to a subject in need thereof an extract of Siraitia grosvenorii residuals as an effective component. The extract of Siraitia grosvenorii residuals has, in an animal model having asthma induced by ovalbumin (OVA), an effect of reducing airway hyper-responsiveness, inhibiting inflammatory cells in bronchoalveolar lavage fluid (BALF), reducing Th2 cytokines (IL-4, IL-5, and IL-13) in BALF, reducing inflammation and tissue damage in lung tissues, inhibiting contraction of airway smooth muscle and airway inflammation, an effect of inhibiting expression of IL-13, TARC, TNF-α, IL-17, and MUC5AC, which is a gene encoding mucus protein, in lung tissues, an effect of reducing the level of ovalbumin-specific IgE in blood serum, and an effect of reducing ROS in alveolar cells which is generated in excess amount due to fine dust.
- Claim:
1. A method for treating respiratory disease, the method comprising administering to a subject in need thereof a composition comprising an extract of Siraitia grosvenorii residuals as an effective component.
- Claim:
2. The method of claim 1, wherein the extract of Siraitia grosvenorii residuals is produced by a process comprising: adding an extraction solvent to dried Siraitia grosvenorii followed by extraction and filtration to remove a supernatant; and adding ethanol to residuals of Siraitia grosvenorii, which remain after removal of the supernatant, to obtain an extract of Siraitia grosvenorii residuals.
- Claim:
3. The method of claim 2, wherein the extraction solvent comprises at least one of water and C1-C4 lower alcohol.
- Claim:
4. The method of claim 1, wherein the respiratory disease is selected from the group consisting of asthma, chronic obstructive pulmonary disease, bronchitis, pharyngolaryngitis, tonsillitis, and laryngitis.
- Claim:
5. The method of claim 1, wherein the respiratory disease is caused by fine dust.
- Claim:
6. The method of claim 1, wherein the composition is prepared in any one formulation selected from a powder, a granule, a pill, a tablet, a capsule, a candy, a syrup, and a drink.
- Claim:
7. The method of claim 1, wherein the composition is included in a functional health food.
- Claim:
8. The method of claim 1, wherein the composition is a pharmaceutical composition.
- Claim:
9. The method of claim 8, wherein the pharmaceutical composition further comprises, in addition to the extract of Siraitia grosvenorii residuals, at least one of a pharmaceutically acceptable carrier, vehicle, and diluent.
- Claim:
10. The method of claim 8, wherein the respiratory disease is caused by fine dust.
- Current International Class:
61; 61; 23; 23
- الرقم المعرف:
edspap.20210138012
Processing Request
No Comments.